114 related articles for article (PubMed ID: 30124440)
21. Cystic Hypersecretory Hyperplasia of Breast.
Singh K; Falkenberry S; Eklund B; Quddus MR
Int J Surg Pathol; 2018 Aug; 26(5):432-433. PubMed ID: 29198159
[No Abstract] [Full Text] [Related]
22. A pictorial journey through variants of ductal carcinoma in situ (DCIS) and DCIS mimickers.
Resetkova E
Clin Breast Cancer; 2012 Oct; 12(5):347-63. PubMed ID: 23040003
[TBL] [Abstract][Full Text] [Related]
23. Diagnosing invasive cystic hypersecretory duct carcinoma of the breast with fine needle aspiration cytology. A case report.
Lee WY; Cheng L; Chang TW
Acta Cytol; 1999; 43(2):273-6. PubMed ID: 10097724
[TBL] [Abstract][Full Text] [Related]
24. Cystic hypersecretory duct carcinoma of the breast. Report of a case with fine-needle aspiration.
Colandrea JM; Shmookler BM; O'Dowd GJ; Cohen MH
Arch Pathol Lab Med; 1988 May; 112(5):560-3. PubMed ID: 2833875
[TBL] [Abstract][Full Text] [Related]
25. [Breast lesion diagnosis: integrating pathology and radiology].
Zonderland HM; van de Vijver MJ; Visser M
Ned Tijdschr Geneeskd; 2011; 155(18):A2967. PubMed ID: 21466724
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer underestimation rate of atypical ductal hyperplasia diagnosed by core-needle biopsy under imaging guidance.
Wiratkapun C; Wibulpholprasert B; Lertsithichai P; Pulpinyo K; Wongwaisayawan S
J Med Assoc Thai; 2005 Apr; 88(4):460-6. PubMed ID: 16146248
[TBL] [Abstract][Full Text] [Related]
27. Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions?
Masood S; Loya A; Khalbuss W
Diagn Cytopathol; 2003 Jun; 28(6):329-34. PubMed ID: 12768640
[TBL] [Abstract][Full Text] [Related]
28. Why the term 'low-grade ductal carcinoma in situ' should be changed to 'borderline breast disease': diagnostic and clinical implications.
Masood S
Womens Health (Lond); 2012 Jan; 8(1):57-62. PubMed ID: 22171775
[TBL] [Abstract][Full Text] [Related]
29. Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?
Punglia RS; Schnitt SJ; Weeks JC
J Natl Cancer Inst; 2013 Oct; 105(20):1527-33. PubMed ID: 24068769
[TBL] [Abstract][Full Text] [Related]
30. Fast 3D Near-infrared breast imaging using indocyanine green for detection and characterization of breast lesions.
Schneider P; Piper S; Schmitz CH; Schreiter NF; Volkwein N; Lüdemann L; Malzahn U; Poellinger A
Rofo; 2011 Oct; 183(10):956-63. PubMed ID: 21972043
[TBL] [Abstract][Full Text] [Related]
31. Validity of needle core biopsy in the histological characterisation of mammary lesions.
Cipolla C; Fricano S; Vieni S; Amato C; Napoli L; Graceffa G; Latteri S; Latteri MA
Breast; 2006 Feb; 15(1):76-80. PubMed ID: 16473738
[TBL] [Abstract][Full Text] [Related]
32. Does intraductal breast cancer spread in a segmental distribution? An analysis of residual tumour burden following segmental mastectomy using tumour bed biopsies.
Jenkinson AD; Al-Mufti RA; Mohsen Y; Berry MJ; Wells C; Carpenter R
Eur J Surg Oncol; 2001 Feb; 27(1):21-5. PubMed ID: 11237487
[TBL] [Abstract][Full Text] [Related]
33. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
34. Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy.
Catteau X; Simon P; Noël JC
Pathol Res Pract; 2012 Apr; 208(4):217-20. PubMed ID: 22445178
[TBL] [Abstract][Full Text] [Related]
35. Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast.
Carder PJ; Garvican J; Haigh I; Liston JC
Histopathology; 2005 Mar; 46(3):320-7. PubMed ID: 15720418
[TBL] [Abstract][Full Text] [Related]
36. Long-term impact of young age at diagnosis on treatment outcome and patterns of failure in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Vicini FA; Shaitelman S; Wilkinson JB; Shah C; Ye H; Kestin LL; Goldstein NS; Chen PY; Martinez AA
Breast J; 2013; 19(4):365-73. PubMed ID: 23815268
[TBL] [Abstract][Full Text] [Related]
37. The clinical significance of breast MRI in the management of ductal carcinoma in situ diagnosed on needle biopsy.
Miyashita M; Amano G; Ishida T; Tamaki K; Uchimura F; Ono T; Yajima M; Kuriya Y; Ohuchi N
Jpn J Clin Oncol; 2013 Jun; 43(6):654-63. PubMed ID: 23592884
[TBL] [Abstract][Full Text] [Related]
38. Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnoses.
Jakate K; De Brot M; Goldberg F; Muradali D; O'Malley FP; Mulligan AM
Am J Surg Pathol; 2012 Apr; 36(4):544-51. PubMed ID: 22314186
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic challenge of low-grade ductal carcinoma in situ.
Onega T; Weaver DL; Frederick PD; Allison KH; Tosteson ANA; Carney PA; Geller BM; Longton GM; Nelson HD; Oster NV; Pepe MS; Elmore JG
Eur J Cancer; 2017 Jul; 80():39-47. PubMed ID: 28535496
[TBL] [Abstract][Full Text] [Related]
40. Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.
Skalova A; Ryska A; Kajo K; Di Palma S; Kinkor Z; Michal M
Histopathology; 2005 Jan; 46(1):43-9. PubMed ID: 15656885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
